|
|
||||||||
Articles |
Departments of Nephrology 1 and Clinical Chemistry2 Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Correspondence to: R.T. Krediet, Department of Nephrology F4-215, Academic Medical Center, Meibergdreef 9 1105 AZ, Amsterdam, The Netherlands. c.n.deboer{at}amc.uva.nl
Background: Chronic exposure to glucose and glucose
degradation products (GDPs) in dialysis solutions is involved in the
pathogenesis of peritoneal neoangiogenesis and fibrosis, potentially leading
to encapsulating peritoneal sclerosis (EPS). High lactate concentrations may
contribute to glucose toxicity by creating a state of pseudohypoxia, which
stimulates the formation of various growth factors.
Objective: To study the effects of long-term peritoneal
exposure to a filter-sterilized pyruvate-buffered solution with a combination
of 3 osmotic agents (amino acids, glycerol, glucose: PYRAGG) on peritoneal
function and morphology.
Methods: Rats were exposed daily for a period of 20
weeks to PYRAGG, or to a conventional heat-sterilized solution (LH), or to a
filter-sterilized solution (LF), after which a peritoneal function test was
done and peritoneal tissue was obtained.
Results: Peritoneal solute and fluid transport
characteristics at 20 weeks were similar in all groups. Fibrosis was most
pronounced in the LH group compared to the others, suggesting an effect of
GDPs. A marked reduction in the number of omental vessels was noted in the
PYRAGG group (59% reduction compared to LH). A modest reduction (28%) was
found in the LF animals. This points to a marked effect of reduced exposure to
glucose.
Conclusions: PYRAGG was more biocompatible than a
filter-sterilized glucose/lactate solution because it did not induce marked
peritoneal abnormalities after long-term exposure. This did not lead to
altered peritoneal transport characteristics. It is likely that further
development of PYRAGG-like solutions will decrease the incidence of
EPS.
KEY WORDS: Pyruvate; glycerol; glucose; amino acids; hypertonicity.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |